A third biosimilar product from Thousand Oaks-based biotech giant Amgen won approval from the U.S. Food and Drug Administration June 13 to treat three types of cancer. Developed in partnership with Dublin pharmaceutical giant Allergan, the biosimilar Kanjinti was shown to be largely the same as Roche’s chemotherapy Herceptin. It was approved to treat metastatic…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
